Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Cancer Vaccines and Antibodies

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4549
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Cancer Vaccines and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Cancer Vaccines and Antibodies.

    To find out more about Triple Analysis: Melanoma, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
3SBio
A&G Pharmaceutical
AB Science
Abbott
AbbVie
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actelion
Actinium Pharmaceuticals
Active Biotech
Adaptimmune
Adherex
Advanced Life Sciences
Advaxis
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Alnylam
AlphaVax
ALSP
Altor BioScience
Ambit Biosciences
Amgen
Amorfix Life Sciences
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Berkeley Lab
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Biocon
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotech Ltd
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celgene
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
CG Therapeutics
Circadian Technologies
CJ Corp
Clavis Pharma
Cosmo Pharmaceuticals
CreaGene
CSL
CuraGen
CureTech
CureVac
Customized Therapeutics
CytImmune Sciences
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
DNAVEC
Dompe
Dong-A
Dr Reddy’s
Dyax
Eisai
Elan
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Ergon Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Flamel Technologies
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
Genomic Systems
GenPat77
Genta
Genticel
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
Glycotope
Gradalis
Green Cross
Hawthorn Pharmaceuticals
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inotek
Inovio
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kaketsuken
KaloBios
Kalypsys
Karyon-CTT
Kiadis
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
MacroGenics
Mannkind
MAT Biopharma
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Momotaro-Gene
Mycenax
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Neuren
NIH
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novogen
Oasmia
Oncalis
OncoMed
OncoMune
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
Oxford BioMedica
Pacific Biotech
Paladin Labs
Panacea
PanGenetics
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
PharmaForm
PharmaMar
Pharmexa
Philogen
PhiloGene
Pierre Fabre
Piramal
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
Protherics
Radient Pharmaceuticals
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
responsif
Rexahn
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
SBI Biotech
Scancell
Seattle Genetics
Shanghai CP Guojian
Shenogen
Shionogi
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spirogen
Stainwei Biotech
Sunesis
Sunol Molecular
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Targepeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Vical
Wilex
VioQuest
Viragen
Virionics
ViroMed
Viventia Biotech
WntResearch
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
YM BioSciences
York Pharma
Zenotech
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
ADXS11-001
AE-37
AEB071
aflibercept
agatolimod
AGS-003
AGS-1C4D4
ALD-518
aldesleukin
alemtuzumab
ALT-801
amatuximab
AME-133
AMG-386
ANZ-207
APO-866
ARRY-438162
astuprotimut-r
Auto TAG vaccine
AV-299
AVX-701
axitinib
bardoxolone methyl
belagenpumatucel-L
belimumab
belinostat
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
bortezomib
BP-GMAX-CD1
brentuximab vedotin
BT-062
Buparlisib
BV-NSCLC-001
Cabozantinib
carlumab
catumaxomab
CB-10-01
CDX-1307
CDX-1401
cetuximab
CG-201
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
cositecan
CreaVax-PC
CT-011
CV-9103
CV-9201
CVac
dalotuzumab
daratumumab
dasatinib
DCVax-prostate
decitabine
denenicokin
denileukin diftitox
denosumab
dinaciclib
dovitinib lactate
E-75
E7449
elotuzumab
EMD-273063
EMD525797
emepepimut-S
endostatin
entinostat
epirubicin
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
fresolimumab
galiximab
ganetespib
ganitumab
gefitinib
gemtuzumab ozogamicin
GI-4000
girentuximab
glembatumumab vedotin
golvatinib
GS-6634
GSK-1120212
GSK-2118436
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
HS-110
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
ICT-107
imatinib mesilate
imMucin
IMO-2055
INCB-24360
inotuzumab ozogamicin
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
IPH-2102
ipilimumab
iratumumab
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
L19-TNFalpha
Lambrolizumab
LEE-011
lenvatinib
LGX818
lintuzumab
LIP-131I
LipoVIL12
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
MetXia
MGN-1601
milatuzumab
milatuzumab-doxorubicin
MKC-1106-MT
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
moxetumomab pasudotox
MVA-BN Her-2 vaccine
naptumomab estafenatox
natalizumab
necitumumab
nilotinib
nimotuzumab
obinutuzumab
ofatumumab
olaratumab
onartuzumab
OncoVAX
Onyvax-105
oregovomab
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
panitumumab
PAT-SC1
peginterferon alfa-2b
perifosine
pertuzumab
PF-4856884
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
RAF-265
ramucirumab
Reditux
retaspimycin
Reximmune-C
RG-7160
rhIFN-alpha
ridaforolimus
rilotumumab
rindopepimut
rintatolimod
rituximab
robatumumab
romiplostim
S-488410
sagopilone
samalizumab
SAR-3419
sargramostim
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sotatercept
sunitinib malate
Survivac
Sym-004
talminogene laherparepvec
Tenarad
tesetaxel
TG-4010
thalidomide
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tocilizumab
trabedersen
TRC-105
tremelimumab
TroVax
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
velimogene aliplasmid
veliparib
veltuzumab
vemurafenib
verpasep caltespen
verubulin
vinflunine ditartrate
vitespen
volociximab
VX-001
YM-155
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Cancer Vaccines and Antibodies.
    To find out more about Triple Analysis: Melanoma, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lymphoma and Prostate Cancer. Learn More


Triple Analysis: Colorectal Cancer, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Prostate Cancer. Learn More


Triple Analysis: Breast Cancer, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the compound strategy of Antibodies. Learn More